Case Study: How an Independent Compounding Pharmacy Achieved PCAB Accreditation Under the Revised USP 797 Standards

Last updated: April 2026

Client details are presented in anonymized form consistent with IHS confidentiality obligations. Bracket placeholders indicate where client-specific data will be inserted prior to publication.

Client Overview

Organization type: [Independent 503A compounding pharmacy / Hybrid compounding and dispensing pharmacy / Hospital pharmacy compounding unit]
Location: [State]
Compounding volume: [X% sterile / X% non-sterile; approximately X compounds per month]
Number of locations: [X]
Staff: [X pharmacists, X pharmacy technicians]
Reason for pursuing PCAB: [e.g., Washington/Ohio nonresident licensure requirement / physician referral network access / M&A due diligence preparation / competitive differentiation]
Prior compliance status: [No prior PCAB; operating under legacy USP 797 (2008 version) procedures]
Engagement start date: [Month, Year]
Survey date: [Month, Year]
Outcome: PCAB Accreditation awarded (36-month cycle)

The Challenge

[Pharmacy name] had operated as a dedicated sterile compounding pharmacy for [X years], building a strong reputation with [X] referring physicians and [X] patient relationships. When the revised USP Chapter 797 achieved final enforceable status on November 1, 2023, replacing the 2008 risk-level framework with the Category 1/2/3 BUD continuum, the pharmacy's existing procedures became substantially non-compliant across multiple domains simultaneously.

Four specific challenges defined the engagement:

1. Designated Person Designation Gap

The pharmacy had no formally designated person responsible for overseeing the compounding quality program. Responsibilities for quality oversight, training, environmental monitoring, and deviation management were informally distributed across [the pharmacist-in-charge and two senior technicians], but no formal DP designation existed with documented responsibilities. Under revised USP 797, this gap constitutes a citation-level deficiency — and carries a 31% PCAB citation rate.

2. Media Fill Testing and Gloved Fingertip Sampling Not Documented

The pharmacy had never conducted formal media fill testing under a documented protocol. Gloved fingertip and thumb sampling had been performed informally, but records did not meet USP 797's semi-annual documentation requirements. Under revised USP 797, all [X] sterile compounding personnel required initial media fill testing and gloved fingertip sampling before they could be documented as qualified to manipulate patient drugs — a foundational gap requiring immediate remediation.

3. SOPs Written to 2008 USP 797 Risk-Level Framework

All [X] existing sterile compounding SOPs referenced the superseded low/medium/high risk-level BUD framework. The revised USP 797's Category 1/2/3 classification system required a comprehensive SOP rewrite — not an update, but a structural replacement of the BUD logic throughout the documentation set. The pharmacy's environmental monitoring frequencies, garbing procedures, and documentation forms all required revision to match the Category framework.

4. State Nonresident Licensure Timeline

[Pharmacy name] was expanding services to [Washington / Ohio] and faced a state board deadline for verifiable PCAB accreditation. The engagement timeline was therefore non-negotiable: accreditation had to be achieved before [date], or the nonresident licensure application could not be submitted.

IHS's Approach

Week 1–2: Comprehensive Gap Assessment

IHS conducted an exhaustive review of all existing SOPs, personnel training records, environmental monitoring logs, equipment calibration documentation, and physical environment against the finalized USP 795, 797, and 800 standards. The gap report identified [X] deficiency categories across [X] priority levels. The Designated Person designation and media fill testing gaps were immediately triage-classified as highest priority — both because of their citation risk and because their remediation required the longest lead time.

Weeks 3–6: Designated Person Designation and SOP Architecture

IHS drafted the formal Designated Person designation for [name], the pharmacy's [Pharmacist-in-Charge / Quality Manager], including a comprehensive role charter covering all responsibilities required under revised USP 795 and 797. Simultaneously, IHS began the SOP rewrite — converting the legacy risk-level framework to the Category 1/2/3 BUD architecture across [X] core procedure documents. The Category framework required restructuring the logic of every SOP that referenced BUD assignment, environmental monitoring frequency, or personnel qualification requirements.

Weeks 7–14: Full SOP Development Cycle

IHS distributed customized SOP chapters in a sequenced 12-week rollout — one major procedure domain per week, allowing pharmacy staff to digest, implement, and demonstrate compliance with each chapter before the next was introduced. Domains covered: cleanroom maintenance and environmental monitoring; garbing and hand hygiene; equipment calibration and maintenance; media fill testing protocol; gloved fingertip and thumb sampling protocol; shipping system validation; deviation and CAPA management; Beyond-Use Date assignment under the Category 1/2/3 framework; hazardous drug handling under USP 800.

Media Fill and Gloved Fingertip Testing Events

IHS coordinated [X] media fill testing events for all [X] sterile compounding personnel. Each event followed the documented protocol, with results reviewed against acceptance criteria and all records produced in PCAB-ready format. All [X] personnel passed initial media fill testing, [X] personnel required additional training and repeat testing before qualification. Gloved fingertip and thumb sampling was conducted for all [X] personnel and documented to semi-annual schedule requirements. IHS built the ongoing sampling calendar and failure response protocol that the pharmacy would use for the full 36-month accreditation cycle.

Weeks 15–18: Mock Survey

IHS conducted a [X]-day mock survey including real-time observation of [X] sterile compounding procedures, environmental monitoring log review, personnel record audit, equipment calibration log review, and shipping validation documentation assessment. The mock survey identified [X] remaining gaps. The most significant finding was [describe finding — e.g., "environmental monitoring logs showing two temperature excursions in the preceding quarter with no documented CAPA response"]. IHS developed a remediation plan for each finding and provided targeted support through resolution.

Week 19: Application Submission

Formal PCAB/ACHC application submitted with complete Preliminary Evidence Report. Dr. Goddard reviewed the full submission package before submission to identify any documentation gaps that might trigger ACHC requests for information. [X / no] pre-submission deficiencies were identified and corrected before filing.

Formal On-Site Survey (Month [X])

ACHC conducted the formal binding on-site survey. IHS prepared all [X] pharmacy staff for surveyor interactions, including clinical observation of aseptic technique, equipment log audit, and personnel record review. Surveyor observations during the [X]-day survey included [describe key surveyor focus areas].

Outcome

[Pharmacy name] received PCAB Accreditation (36-month cycle) following its [Month Year] formal on-site survey. Survey outcome:

[X] citations received — all [minor / addressing documentation format issues / none requiring corrective action prior to accreditation award]
No conditions requiring delay of accreditation award
[X] surveyor commendations, including specific recognition of [describe commended area — e.g., "the pharmacy's comprehensive media fill testing documentation and the Designated Person's demonstrated operational command of the quality program"]

Operational Impact

State licensure: Nonresident compounding pharmacy license application submitted to [Washington / Ohio] board of pharmacy [X days] after PCAB accreditation award; license granted [X days] later
Physician referral growth: [Describe outcome — e.g., "[X] new physician referral relationships established within [X months] of PCAB accreditation, citing AMA recommendation as the trigger for switching from a non-accredited compounding source"]
Payer credentialing: [Describe outcome if applicable]
Internal quality improvement: [Describe — e.g., "The Designated Person role, previously non-existent, became a functioning quality leadership position. Environmental monitoring excursion response time improved from [X days] to [X days] following CAPA protocol implementation."]

Key Lessons for Pharmacies Preparing for PCAB Accreditation Under Revised USP 797

Start Media Fill Testing Before Anything Else

Media fill testing qualification is a prerequisite for sterile compounding staff to be documented as qualified — and the testing events take time to schedule, execute, and document. Organizations that begin media fill testing late in the preparation timeline risk arriving at the formal survey with personnel who cannot be documented as fully qualified. Begin media fill testing at the start of the engagement, not at the end.

The Designated Person Role Is Not a Document — It Is a Function

PCAB surveyors do not just check that a DP designation document exists. They assess whether the designated person can demonstrate operational command of the quality program: environmental monitoring trends, deviation history, CAPA documentation, and training records. The DP designation must be backed by a person who actually performs the function, not just signs the document.

SOP Architecture Matters More Than SOP Length

The most common SOP deficiency in PCAB surveys is not missing content — it is structural incoherence. SOPs that reference the old risk-level framework while describing new Category-based procedures create contradictions that surveyors cite. IHS's SOP development approach rebuilds from the Category 1/2/3 architecture at the foundation level, not as a patch on top of the existing document structure.

Environmental Monitoring Excursions Must Have Documented CAPAs

Every environmental monitoring excursion — every temperature deviation, every out-of-range viable sampling result — must have a documented CAPA. Excursions without CAPAs are automatic citations. IHS builds excursion response workflows directly into the environmental monitoring SOP so that the CAPA process begins the moment an excursion is recorded.

Is Your Pharmacy Preparing for PCAB Accreditation?

Schedule a no-obligation gap assessment with Thomas G. Goddard, JD, PhD. IHS will assess your current USP 795/797/800 compliance posture and give you a clear phased roadmap to PCAB accreditation.

Schedule Your PCAB Gap Assessment